Circumferential laryngopharyngectomy with free jejunal transfer for hypopharyngeal cancer: a retrospective cohort analysis of outcomes and complications - Summary - MDSpire

Circumferential laryngopharyngectomy with free jejunal transfer for hypopharyngeal cancer: a retrospective cohort analysis of outcomes and complications

  • By

  • Alissa De Baets

  • Davide Di Santo

  • Ann Goeleven

  • Katarina Segers

  • Thomas Nevens

  • Albert Wolthuis

  • Vincent Vander Poorten

  • Jeroen Meulemans

  • June 24, 2026

  • 0 min

Share

Objective:

To evaluate the oncological and functional outcomes of total laryngopharyngectomy (TLP) with free jejunal transfer (FJT) in patients with hypopharyngeal squamous cell carcinoma (HSCC).

Approach:
  • Study Design: A monocentric retrospective cohort analysis of 22 patients treated with TLP and FJT reconstruction for HSCC at a tertiary care institution between 2000 and 2023.
Key Findings:
  • 22patientsincluded(18.2%female,meanage65.6years).Meanfollow-uptimewas3.9years.PrimaryTLPperformedin8patients(36.4%),salvageTLPin14patients(63.6%).SuccessfulFJTachievedin95.5%ofpatients;1FJTfailure(4.5%).Pharyngocutaneousfistula(PCF)occurredin27.3%ofpatients.Two-yearoverallsurvival(OS)ratewas52.3%,five-yearOSratewas26.9%.Disease-specificsurvival(DSS)rateswere54.7%attwoyearsand42.8%atfiveyears.Completeoralintakeandvoicerehabilitationachievedin68.2%and52.3%ofpatients,respectively.
Interpretation:

FJT is a viable reconstructive option following TLP, with acceptable functional outcomes and favorable oncological results.

Limitations:
  • Retrospective design may introduce selection bias.
  • Small sample size limits generalizability of findings.
  • Lack of long-term follow-up data.
Conclusion:

FJT is an effective reconstructive method post-TLP, with good oncological outcomes and functional results, though improvements are needed.

Original Source(s)

Circumferential laryngopharyngectomy with free jejunal transfer for hypopharyngeal cancer: a retrospective cohort analysis of outcomes and complications

  • by Alissa De Baets, Davide Di Santo, Ann Goeleven, Katarina Segers, Thomas Nevens, Albert Wolthuis, Vincent Vander Poorten, Jeroen Meulemans

  • June 24, 2026

Related Content

MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial

Multiple primary head and neck cancers: a scenario-based framework for diagnosis and modern multidisciplinary management

Pilot study of topical imiquimod combined with pembrolizumab for unresectable cutaneous metastatic melanoma